Frequently asked questions
The global cirrhosis market was valued at USD 658.9 Million in 2022.
The cirrhosis market is expected to grow at a CAGR of 4.2% between 2023 and 2030, reaching USD 915.71 Million in 2030.
Alcoholic cirrhosis is the leading segment by etiology, holding over 35% share in value in 2022.
The hospitals and clinics segment governs the global demand for cirrhosis, holding a massive share of over 44% in 2022.
The medications (antivirals, immunosuppressants) segment will post the highest CAGR over the projection period.
North America is fueling the growth of the cirrhosis industry, with over one-third share in 2022.
The top players include B. Braun Medical Inc., AstraZeneca, Histogen Inc., Stempeutics Research Pvt Ltd, Epic Research & Diagnostics Inc, Bayer AG, Sequana Medical AG, Pfizer Inc., Merck & Co. Inc., Novartis AG, and Others.
The major market drivers are the increasing prevalence of liver diseases, a growing aging population, and advancements in medical technologies and treatments.
The major market restraints of the cirrhosis industry encompass the high cost of treatments, limited availability of effective therapies, and challenges related to early diagnosis and disease management.
The major market opportunities in the cirrhosis industry involve the development of novel therapeutic interventions, expanding healthcare infrastructure in emerging markets, and increasing awareness about liver health and prevention strategies.